Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients
August 04, 2020 02:00 ET
|
Tiziana Life Sciences Plc
Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and...
Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
August 03, 2020 02:00 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics...
Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
August 03, 2020 00:10 ET
|
Tiziana Life Sciences plc
New York and London, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics...
Tiziana Life Sciences plc: Total Voting Rights
July 31, 2020 12:00 ET
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the...
Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients
July 31, 2020 02:00 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM
July 30, 2020 11:31 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of...
Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020
July 30, 2020 02:00 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
Exercise of Warrants and Issue of Equity and Total Voting Rights
July 24, 2020 02:00 ET
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
Tiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment
July 20, 2020 10:17 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel...
Results of Annual General Meeting
July 16, 2020 07:23 ET
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the...